PRESS RELEASES

Date	Title
Sep 6, 2022	Ardelyx to Participate in Upcoming Investor Conferences
Aug 4, 2022	Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Aug 2, 2022	Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
Jul 28, 2022	Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
Jul 1, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
Jun 30, 2022	Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
Jun 21, 2022	Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
Jun 3, 2022	Ardelyx to Present at the Jefferies 2022 Healthcare Conference
May 24, 2022	Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 17, 2022	Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com